Generic statins preferred to simvastatin plus ezetimibe in kidney disease: SHARP cost-effectiveness
- 19 November 2015
A new publication by HERC reports the cost-effectiveness results of simvastatin plus ezetimibe for cardiovascular prevention in Chronic Kidney disease (CKD) using data of the Study of Heart and Renal Protection (SHARP). The key result is that while simvastatin plus ezetimibe prevented major atherosclerotic events in SHARP, other less costly statin regimens are cost-effective for reducing cardiovascular risk in CKD.
The article can be found online here.